Cover Image
Market Research Report

Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025

Published by Grand View Research, Inc. Product code 656148
Published Content info 140 Pages
Delivery time: 2-3 business days
Price
Back to Top
Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025
Published: May 29, 2018 Content info: 140 Pages
Description

The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 5.2% during the forecast period. Rising prevalence of Multidrug Resistant (MDR) tuberculosis and HIV-tuberculosis co-infection is likely to drive the market during the forecast period. According to WHO, in 2017, the annual incidence of tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection cases per year, i.e., 87,000.

The TB drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. The Nix-TB trial currently being conducted by TB Alliance in conjunction with Janssen Pharmaceuticals involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which promises a cure for Extensively Drug Resistant (XDR) form of the disease within 6-9 months.

Apart from competitive dynamics, license agreements among players are providing opportunities for emerging drug manufacturers to grow in this space. In September 2015, Dishman Group received a license agreement from Janssen Pharmaceutica NV, subsidiary of Johnson & Johnson Services, LLC to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline), intended for MDR TB treatment. Dishman, apart from being an API supplier for Janssen's novel drug, is now listed as a licensed API manufacturer with the EMA, USFDA, and several Asian regulatory authorities.

Further key findings from the report suggest:

Collaborative efforts among international organizations and pharmaceutical players are spurring drug development and treatment access, which is expected to propel the growth of the tuberculosis drugs market

In March 2015, a collaboration between the United States Agency for International Development (USAID) and the Janssen Global Services, LLC was undertaken to provide the drug bedaquiline free of cost to eligible MDR-tuberculosis patients

Based on disease type, the active tuberculosis drugs segment accounted for the largest share of 87.3% in 2016. If undiagnosed, latent tuberculosis has the potential to transform to the active form, which has led countries in Europe and North America to focus on early diagnosis and preventive measures

Based on therapy type, second-line therapy drugs led the market with a share of 60.4% in 2016. Rising incidence and higher treatment cost structure of MDR tuberculosis, coupled with increasing treatment access, is spurring market growth

Regionally, Asia Pacific held a major market share and is expected to retain its dominance during the forecast period due to high disease incidence and gradual improvement in patient medication adherence rates

Europe is likely to witness significant growth over the next decade due to high MDR-TB burden, along with improved focus on LTBI treatment drugs

Some of the key players in the tuberculosis drugs market are Johnson & Johnson (J&J) Services, Lupin, Pfizer, Novartis AG, Macleods Pharmaceuticals Limited, and Otsuka Pharmaceutical Co., Ltd.

Table of Contents
Product Code: GVR-2-68038-500-7

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise market calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based segment share calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Drivers Analysis
      • 3.1.1.1 Global plan against drug-resistant TB drives diagnosis and treatment enrollment
      • 3.1.1.2 HIV burden fuels LTBI case counts
    • 3.1.2 Market Restraints Analysis
      • 3.1.2.1 High drug cost
      • 3.1.2.2 Poor regulation and lack of awareness in developing countries
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Tuberculosis Drugs/Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Tuberculosis Drugs/Therapeutics Market: Therapy Type & Trend Analysis

  • 4.1 Tuberculosis Drugs/Therapeutics Market: Therapy Type Movement Analysis
    • 4.1.1 First-Line Therapy
      • 4.1.1.1 First-line therapy market, 2014 - 2025 (USD Million)
    • 4.1.2 Second-Line Therapy
      • 4.1.2.1 Second-line therapy market, 2014 - 2025 (USD Million)

Chapter 5 Tuberculosis Drugs/Therapeutics Market: Disease Type & Trend Analysis5

  • 5.1 Latent TB
    • 5.1.1 Latent TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 5.2 Active TB
    • 5.1.2 Active TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)

Chapter 6 Market Categorization 2: Regional Estimates & Trend Analysis

  • 6.1 Tuberculosis Drugs/Therapeutics Market Share, By Region, 2014 & 2025
  • 6.2 North America
    • 6.2.1. North America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD million)
  • 6.3 Europe
    • 6.3.1 Germany
      • 6.3.1.1 Germany tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.3.2 France
      • 6.3.2.1 France tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.3.3 UK
      • 6.3.3.1 UK tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.2 India
      • 6.4.2.1 India tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.4.4 Philippines
      • 6.4.4.1 Philippines tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America tuberculosis Drugs/Therapeutics market, 2014 - 2026 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • 6.6 Middle East & Africa
    • 6.6.1 Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
    • 6.6.3 Nigeria
      • 6.6.3.1 Nigeria tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
  • 7.3 Company Profiles
    • 7.3.1 Johnson & Johnson Services, LLC
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product overview
      • 7.3.1.4 Business strategies
      • 7.3.1.5 SWOT analysis (Johnson & Johnson Services, LLC)
    • 7.3.2 Lupin
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product Overview
      • 7.3.2.4 Business growth strategies
      • 7.3.2.5 SWOT analysis (Lupin)
    • 7.3.3 Novartis AG
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product overview
      • 7.3.3.4 Business strategies
      • 7.3.3.5 SWOT analysis (Novartis AG)
    • 7.3.4 Macleods Pharmaceuticals Ltd.
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product overview
      • 7.3.4.4 Business strategies
      • 7.3.4.5 SWOT analysis (Macleods Pharmaceuticals Ltd)
    • 7.3.5 Otsuka Pharmaceutical Co., Ltd.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product Overview
      • 7.3.5.4 Business strategies
      • 7.3.5.5 SWOT analysis (Otsuka Pharmaceuticals)
    • 7.3.6 Pfizer
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product overview
      • 7.3.6.4 Business Strategies
      • 7.3.6.5 SWOT analysis (Pfizer)

Chapter 8 Market Outlook

  • 7.1 Market Scenario
  • 7.2 Pipeline Analysis
    • 7.2.1 Repurposed Drugs/Therapeutics
    • 7.2.2 Current Regimen Trials
    • 7.2.3 Promising Therapies

List of Tables

  • TABLE 1 North America tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 2 North America tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 3 North America tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 5 U.S. tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 6 Canada tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 7 Canada tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 8 Europe tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 9 Europe tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 10 Europe tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 11 Germany tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 12 Germany tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 13 France tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 14 France tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 15 U.K. tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 16 U.K. tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 17 Statistics for TB in high burden countries in APAC region, 2016
  • TABLE 18 Asia Pacific tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 19 Asia Pacific tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 20 Asia Pacific tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 21 India tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 22 India tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 23 China tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 24 China tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 25 Philippines tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 26 Philippines tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 27 Latin America TB cases, 2013
  • TABLE 28 Latin America tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 29 Latin America tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 30 Latin America tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 31 Brazil tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 32 Brazil tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 33 Mexico tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 34 Mexico tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 35 Africa tuberculosis Drugs/Therapeutics market, by country, 2014 - 2025 (USD Million)
  • TABLE 36 Africa tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 37 Africa tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 38 South Africa tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 39 South Africa tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)
  • TABLE 40 Nigeria tuberculosis Drugs/Therapeutics market, by disease type, 2014 - 2025 (USD Million)
  • TABLE 41 Nigeria tuberculosis Drugs/Therapeutics market, by therapy type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary 2016, (USD Million)
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Average treatment cost, per case (2016 USD), in the U.S.
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 Tuberculosis Drugs/Therapeutics market - PESTLE analysis
  • FIG. 14 Porter's five forces analysis
  • FIG. 15 Drugs/Therapeutics in development for tuberculosis
  • FIG. 16 Tuberculosis Drugs/Therapeutics market, Therapy outlook: Key takeaways
  • FIG. 17 Tuberculosis Drugs/Therapeutics market: Therapy movement analysis
  • FIG. 18 Treatment of tuberculosis in adult and children
  • FIG. 19 First-line Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 20 Treatment of tuberculosis with second-line Drugs/Therapeutics
  • FIG. 21 Second-line therapy market, 2014 - 2025 (USD Million)
  • FIG. 22 Tuberculosis Drugs/Therapeutics market: Disease type movement analysis
  • FIG. 23 LTBI treatment regimen
  • FIG. 24 Latent TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 25 Active TB Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 26 Regional market place: Key takeaways
  • FIG. 27 Tuberculosis Drugs/Therapeutics market: Regional outlook, 2014 & 2025
  • FIG. 28 North America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 29 U.S. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 30 Canada tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD million)
  • FIG. 31 Europe tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 32 Germany tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 33 France tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 34 U.K. tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 35 Asia Pacific tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 36 India tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 37 China Tuberculosis Drugs/Therapeutics Market, 2014 - 2025 (USD Million)
  • FIG. 38 Philippines Tuberculosis Drugs/Therapeutics Market, 2014 - 2025 (USD Million)
  • FIG. 39 Latin America tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 40 Brazil tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 41 Mexico tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 42 Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 43 South Africa tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 44 Nigeria tuberculosis Drugs/Therapeutics market, 2014 - 2025 (USD Million)
  • FIG. 45 Strategy framework
  • FIG. 46 SWOT analysis (Johnson & Johnson)
  • FIG. 47 SWOT analysis (Lupin)
  • FIG. 48 SWOT analysis (Novartis AG)
  • FIG. 49 SWOT analysis (Macleods Pharmaceuticals Ltd)
  • FIG. 50 SWOT Analysis (Otsuka Pharmaceuticals)
  • FIG. 51 SWOT analysis (Pfizer)
Back to Top